NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
Clinical Trials
300 trialsNCT05646758 2024-03-18
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03975907 2024-03-12
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Unknown
NCT05066607 2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2 Unknown
NCT05697913 2024-03-06
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
Hospital Galdakao-Usansolo
Phase NA Unknown
NCT03428373 2024-02-29
RithMM
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2/3 Unknown
NCT05346198 2024-02-23
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT06258096 2024-02-14
LI-TASTE
Academic Centre for Dentistry in Amsterdam
Phase NA Unknown
NCT05840107 2024-02-13
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT05478993 2024-01-31
SPODUMENE
Peking University People's Hospital
Phase 2 Unknown
NCT06223646 2024-01-25
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Unknown
NCT06203145 2024-01-12
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Peking University First Hospital
Phase NA Unknown
NCT05308875 2024-01-05
Efficacy and Safety Evaluation of PD1-BCMA-CART
Bioray Laboratories
Phase NA Unknown
NCT04714827 2023-12-29
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT04727008 2023-12-12
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Sichuan University
Phase 1 Unknown
NCT04877275 2023-12-06
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT05280275 2023-12-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Phase 1/2 Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT06116734 2023-11-03
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Unknown
NCT04519476 2023-10-31
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Phase 1 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05378971 2023-10-04
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
LanZhou University
Phase NA Unknown
NCT06060080 2023-09-29
Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma
Chongqing University Cancer Hospital
Phase NA Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT04309981 2023-08-28
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Phase 1/2 Unknown
NCT05995808 2023-08-16
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Sohag University
Phase NA Unknown
NCT04211259 2023-08-07
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Unknown
NCT05005299 2023-08-01
VICTORY
Melbourne Health
Phase 1 Unknown
NCT05964270 2023-07-27
ITUMM
Isala
Phase NA Unknown
NCT05951816 2023-07-19
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase 1 Unknown
NCT04836871 2023-07-13
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
Phase 1 Unknown
NCT03695744 2023-07-10
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
Phase 2 Unknown
NCT04814615 2023-06-27
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Hoag Memorial Hospital Presbyterian
Phase 2 Unknown
NCT05920876 2023-06-27
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03809780 2023-06-22
LENDER
Kosin University Gospel Hospital
Phase 2 Unknown
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT03090659 2023-06-12
LEGEND-2
Nanjing Legend Biotech Co.
Phase 1/2 Unknown
NCT05855122 2023-06-02
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT05271682 2023-05-16
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05857982 2023-05-15
Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT01685814 2023-04-27
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
Phase 3 Unknown
NCT05749133 2023-04-20
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT04272151 2023-04-18
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04861480 2023-04-18
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT05438394 2023-04-14
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Peking University People's Hospital
Phase 1 Unknown